Advertisement

Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x100px
Organisation › Details

Nanobiotix S.A. (Euronext Paris: NANO, Nasdaq: NBTX)

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell. The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges. Nanobiotix’s first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies. Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. *

 

Period Start 2003-01-01 established
  Group Nanobiotix (Group)
Products Industry nanobiotechnology
  Industry 2 oncology
Persons Person Lévy, Laurent (NanoBiotix 201103 CEO)
  Person 2 Mauberna, Philippe (Nanobiotix 201807 CFO)
     
Region Region Paris
  Country France
  Street 60 Rue de Wattignies
Bat B 3rd Floor
  City 75012 Paris
  Tel +33-1-4026-0470
    Address record changed: 2024-01-05
     
Basic data Employees C: 51 to 100 (2017-12-31)
  Currency EUR
  Annual sales 3,721,525 (revenue, total (2017) 2017-12-31)
  Profit -26,143,249 (2017-12-31)
  Cash 47,200,000 (2017-12-31)
     
    * Document for »About Section«: Nanobiotix S.A.. (4/4/19). "Press Release: Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval". Paris & Cambridge, MA.
     
   
Record changed: 2024-02-12

Advertisement

Picture Berlin Partner Top News Captain T Cell Therapies 650x200px

More documents for Nanobiotix (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px




» top